CoChat

Efficacy and safety of ezetimibe co‐administered with simvastatin in thiazolidinedione‐treated type 2 diabetic patients

Gaudiani, L. M., Lewin, A., Meneghini, L., Perevozskaya, I., Plotkin, D., Mitchel, Y., Shah, S. · 2005 · Diabetes, Obesity and Metabolism
Cited by 73

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aim: In patients with type 2 diabetes mellitus (T2DM), combination therapy is usually required to optimize glucose metabolism as well as to help patients achieve aggressive targets for low‐density lipoprotein cholesterol (LDL‐C) and other lipid parameters associated with cardiovascular risk. The thiazolidinediones (TZDs) are increasingly being used for both their blood glucose‐lowering properties and their modest beneficial effects on triglycerides (TG) and high‐density lipoprotein cholesterol (HDL‐C). Ezetimibe, an intestinal cholesterol absorption inhibitor, has a mechanism of action that differs from that of statins, which inhibit hepatic cholesterol synthesis. We compared the lipid‐modifying efficacy and safety of adding ezetimibe to simvastatin, vs. doubling the dose of simvastatin, in TZD‐treated T2DM patients. Methods: This was a randomized, double‐blind, parallel group, multicentre study in T2DM patients, 30–75 years of age, who had been on a stable dose of a TZD for at least 3 months and had LDL‐C > 2.6 mmol/l (100 mg/dl) prior to study entry. Other antidiabetic medications were also allowed. Following 6 weeks of open‐label simvastatin 20 mg/day, patients were randomized to the addition of either blinded ezetimibe 10 mg/day (n = 104) or an additional blinded simvastatin 20 mg/day (total simvastatin 40 mg/day; n = 110) for 24 weeks. Patients were stratified according to TZD type and dose (pioglitazone 15–30 vs. 45 mg/day; rosiglitazone 2–4 vs. 8 mg/day). Results: LDL‐C was reduced more (p < 0.001) by adding ezetimibe 10 mg to simvastatin 20 mg (−20.8%) than by doubling the dose of simvastatin to 40 mg (−0.3%). Ezetimibe plus simvastatin 20 mg also produced significant incremental reductions in non‐HDL‐C (p < 0.001), very low‐density lipoprotein cholesterol (p < 0.05) and apolipoprotein B (p < 0.001) relative to simvastatin 40 mg. There were no differences between the groups with respect to changes in TG and HDL‐C levels, and both treatments were well tolerated. Conclusions: Co‐administration of ezetimibe with simvastatin, a dual inhibition treatment strategy targeting both cholesterol synthesis and absorption, is well tolerated and provides greater LDL‐C‐lowering efficacy than increasing the dose of simvastatin in T2DM patients taking TZDs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2004.00420.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 73

Metadata

Authors
Gaudiani, L. M., Lewin, A., Meneghini, L., Perevozskaya, I., Plotkin, D., Mitchel, Y., & Shah, S.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2004-12-07
Volume
7
Issue
1
Pages
88-97
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2124186024
Cited by
73
References
9
FWCI
8.48
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of ezetimibe co‐administered with simvastatin in thiazolidinedione‐treated type 2 diabetic patients. https://app.cochat.ai/papers/10.1111/j.1463-1326.2004.00420.x
The paper
Gaudiani, L. M., Lewin, A., Meneghini, L., Perevozskaya, I., Plotkin, D., Mitchel, Y., & Shah, S. (2005). Efficacy and safety of ezetimibe co‐administered with simvastatin in thiazolidinedione‐treated type 2 diabetic patients. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2004.00420.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.